GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChromaDex Corp (FRA:OCD1) » Definitions » Investments And Advances

ChromaDex (FRA:OCD1) Investments And Advances : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is ChromaDex Investments And Advances?

ChromaDex's Investments And Advances for the quarter that ended in Mar. 2024 was €0.00 Mil.


ChromaDex Investments And Advances Historical Data

The historical data trend for ChromaDex's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChromaDex Investments And Advances Chart

ChromaDex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ChromaDex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ChromaDex Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


ChromaDex (FRA:OCD1) Business Description

Traded in Other Exchanges
Address
10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segment namely Consumer Products, Ingredients segment and Analytical Reference Standards and Services. Majority of the revenue is earned from Consumer Products segment.

ChromaDex (FRA:OCD1) Headlines

No Headlines